Description

Tesamorelin UK – 6/3/3mg Research Peptide Blend

Product Overview

Tesamorelin UK research demand has grown steadily following the compound’s approval in the United States for HIV-associated lipodystrophy. For laboratories looking to source Tesamorelin UK, this 6/3/3mg blend combines three complementary growth hormone secretagogues in a single vial. Tesamorelin is a synthetic 44-amino acid analogue of human growth hormone-releasing factor (GRF), modified with a trans-3-hexenoyl moiety at the N-terminal tyrosine residue to extend its half-life . The full sequence is documented in the KEGG Drug Database as N-(trans-3-hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 .

This Tesamorelin UK research blend combines 6mg Tesamorelin with 3mg CJC-1295 and 3mg Ipamorelin in a single lyophilized vial. CJC-1295 is a synthetic 29-amino acid GHRH analogue with substitutions at positions 2, 8, 15, and 27, documented in the FDA substance registration system . Ipamorelin is a selective pentapeptide ghrelin receptor agonist with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, as listed in the FDA peptide test documentation .

Researchers who source Tesamorelin UK often do so because the three components target complementary pathways within the growth hormone axis. Tesamorelin and CJC-1295 activate GHRH receptors on the pituitary, while Ipamorelin activates the ghrelin receptor (GHSR-1a). This combination is studied for investigating pulsatile GH secretion, body composition changes, and metabolic regulation in laboratory models.

Regulatory Notice: Tesamorelin holds no UK marketing authorisation and is not available via routine NHS prescribing. UK medical professionals have been warned that none of these peptides currently hold MHRA approval for human therapeutic use, and the “research only” label does not provide legal immunity if human use is implied . This Tesamorelin UK product is supplied strictly for laboratory research purposes only.

Product Specifications

Mechanism of Action

Tesamorelin – GHRH Receptor Agonism

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating endogenous growth hormone secretion. Unlike exogenous GH administration, Tesamorelin restores pulsatile GH release, which is considered a more physiological approach for reducing visceral adipose tissue . A meta-analysis of randomised controlled trials published in ScienceDirect found that Tesamorelin significantly reduced visceral fat (MD=-1.18 kg), trunk fat (MD=-1.18 kg), hepatic fat percentage (MD=-4.28%), and waist circumference (MD=-1.61 cm), while increasing lean body mass (MD=1.42 kg) . Researchers sourcing Tesamorelin UK for metabolic studies frequently cite this meta-analysis.

CJC-1295 – Extended-Half-Life GHRH Analogue

CJC-1295 is a GHRH analogue designed with four amino acid substitutions to resist enzymatic degradation. The free base form contains a maleimidopropionyl moiety at the lysine residue, enabling covalent binding to serum albumin for extended circulation time. When co-administered with a GHRP such as Ipamorelin, research models demonstrate synergistic GH release exceeding the sum of either compound alone.

Ipamorelin – Selective Ghrelin Receptor Agonist

Ipamorelin activates the ghrelin receptor (GHSR-1a), triggering GH release through a separate pathway from GHRH. The pentapeptide’s defining characteristic is its selectivity: preclinical research has shown it releases GH at levels comparable to GHRP-6 without the cortisol, prolactin, or ACTH elevation observed with earlier secretagogues.

Synergistic Research Model

The combination of a GHRH analogue (Tesamorelin or CJC-1295) with a GHRP (Ipamorelin) is studied for its capacity to amplify GH pulse amplitude through dual receptor engagement. GHRH receptor activation increases intracellular cAMP and calcium, while GHSR-1a activation provides an independent stimulatory signal. Research models indicate this dual-pathway approach produces greater GH release than either mechanism alone, which is why Tesamorelin UK blends attract interest from growth hormone researchers.

Research Applications

Body Composition and Visceral Fat Research

Tesamorelin is the most clinically characterised GHRH analogue for visceral adipose tissue reduction. A randomised controlled trial in abdominally obese subjects with reduced GH secretion found that Tesamorelin 2 mg daily for 12 months reduced visceral adipose tissue by 35 cm² compared with placebo, alongside significant reductions in triglycerides and C-reactive protein . The ClinicalTrials.gov registry documents ongoing studies examining Tesamorelin’s effects on body composition and adipose tissue biology in HIV-associated lipodystrophy .

Hepatic Fat and Metabolic Research

The meta-analysis published in 2026 found Tesamorelin reduced hepatic fat percentage by 4.28% across pooled studies, suggesting potential relevance for metabolic dysfunction-associated steatotic liver disease (MASLD) research . Additional research has examined Tesamorelin’s effects on muscle fat infiltration and muscle area in adults with HIV . UK laboratories investigating Tesamorelin UK for hepatic endpoints often pair it with CJC-1295 to extend the GHRH signal.

Growth Hormone Axis Studies

The three-peptide blend enables investigation of GHRH and ghrelin receptor co-activation within a single experimental system. Researchers can compare the combined effect against each component alone to characterise receptor crosstalk and downstream signalling. For anyone sourcing Tesamorelin UK for receptor-level work, this blend provides all three agonists in a fixed ratio.

Pharmacokinetic Research

Tesamorelin’s half-life is extended by its N-terminal trans-3-hexenoyl modification, which reduces susceptibility to dipeptidyl peptidase IV cleavage. CJC-1295’s albumin-binding property further extends its circulation time. The differing half-lives within this blend are relevant for designing time-course experiments, particularly for researchers comparing Tesamorelin UK formulations with single-compound alternatives.

Quality and Purity

Each batch of Cocer Peptides Tesamorelin UK blend undergoes quality control aligned with research-grade peptide standards:

• ≥99% purity verified by HPLC

• Mass spectrometry identity confirmation for all three components

• Batch/lot number matching the vial label

• Certificate of Analysis (COA) available on request

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned against purchasing unlicensed medicines and research peptides online, noting that such products may be contaminated, mislabelled, or of unknown potency . Batch-level analytical documentation is therefore essential when sourcing Tesamorelin UK for research reproducibility.

Frequently Asked Questions

What is Tesamorelin UK research used for?

Tesamorelin UK research focuses on growth hormone secretion, visceral adipose tissue, and body composition. The 6/3/3mg blend adds CJC-1295 and Ipamorelin for research into synergistic GHRH/GHRP co-activation.

Is Tesamorelin legal in the UK?

Tesamorelin holds no UK marketing authorisation and is not available via routine NHS prescribing. Any UK clinical use would require importation as an unlicensed medicine on a named-patient basis, with full prescriber responsibility . This Tesamorelin UK product is supplied for research purposes only.

What is the composition of this blend?

Each vial contains 6mg Tesamorelin, 3mg CJC-1295, and 3mg Ipamorelin (12mg total peptide content).

How should this blend be stored?

Store lyophilized powder at -20°C, protected from light and moisture. Reconstituted material should be used promptly following standard laboratory protocols.

Is this product suitable for human use?

No. This product is supplied strictly for research purposes only and is not intended for human or veterinary use. None of the peptides in this blend hold MHRA marketing authorisation for human therapeutic use .

Conclusion

The Tesamorelin UK 6/3/3mg research blend with CJC-1295 and Ipamorelin represents a multi-target tool for investigating growth hormone axis pharmacology. Tesamorelin provides the most clinically documented GHRH analogue component, while CJC-1295 extends the GHRH signal and Ipamorelin adds ghrelin receptor engagement. For UK researchers seeking Tesamorelin UK for laboratory applications, this blend offers documented composition, ≥99% purity, and batch-specific COA support. Those sourcing Tesamorelin UK from Cocer Peptides receive a fixed-ratio blend designed for reproducible growth hormone axis studies.

Ready to Advance Your Research?

Order the Tesamorelin UK 6/3/3mg research blend for your laboratory today.

Shop Tesamorelin Blend Now | Contact Our Research Team